Episode 1, Part 3 of PharmTech AI Pulse Check covers why INTerpath-001's AI isn't ChatGPT and names pharma manufacturing's biggest AI governance gaps.
|Articles|July 2, 2016
- Pharmaceutical Technology-07-02-2016
- Volume 40
- Issue 7
Modular Bioreactor Simplifies Process Development
The ambr 250 mini benchtop bioreactor system from Sartorius Stedim Biotech can be used for parallel fermentation and cell culture.
The ambr 250 mini benchtop bioreactor system from Sartorius Stedim Biotech can be used for parallel fermentation and cell culture. The system combines a unique single-use bioreactor vessel and expandable system design for process development. The new ambr 250 modular system consists of a workstation with two, four, six, or eight single-use bioreactors, with a working volume range of 100-250 mL. These mini bioreactors, based on the same stirred tank bioreactors in the high throughput system, contain impellers suitable for fermentation or cell culture, and scale up to larger bioreactors. They are also fully integrated with liquid reservoirs and syringe pumps, allowing rapid experimental set up and turn around, thus significantly increasing lab efficiency. Once installed, the bioreactor has all the required process services for parameter control, including pH, DO, temperature, and agitation. Feeds can also be delivered from the reagent reservoirs via syringe pumps into the bioreactor. One control unit is capable of controlling up to eight bioreactor stations independently using a touch screen user interface.
Articles in this issue
about 10 years ago
FDA and Manufacturers Intensify Concerns about Data Integrityabout 10 years ago
Planning a Biologics Facility Start Upabout 10 years ago
Solid-Dosage Packaging Trendsabout 10 years ago
Quality System for a Regulatory Affairs Departmentabout 10 years ago
Data Integrity Challenges in Manufacturingabout 10 years ago
Bio/Pharma Funding Challenges Could Hurt CDMOs in 2017about 10 years ago
Cleaning Bioreactors and Fermenters with CIP Systemsabout 10 years ago
Maximize Efficiency in Tooling Maintenanceabout 10 years ago
Recognizing Pharma Industry Excellenceabout 10 years ago
Expanding the Chiral ToolboxRelated to this article
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Richard Jaenisch weighs how FDA's new NAM rule could reshape preclinical testing and what CMC teams should do now, on Manufacturing Intelligence.
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.
Merck licenses SciBrunch's preclinical KRAS G12D inhibitor for $2.13B, raising tech transfer and scale-up questions for oral cancer drug development.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.
Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.